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IMPORTANCE Blood pressure (BP) lowering is considered neuroprotective in patients with
cerebral small vessel disease; however, more intensive regimensmay increase cerebral
hypoperfusion. This study examined the effect of standard vs intensive BP treatment on
cerebral perfusion in patients with severe small vessel disease.
OBJECTIVE To investigate whether standard vs intensive BP lowering over 3 months causes
decreased cerebral perfusion in small vessel disease.
DESIGN, SETTING, ANDPARTICIPANTS This randomized clinical trial tookplace at 2English
universitymedical centers. Patientswere randomizedvia a central online system (in a
1:1 ratio). Seventypatientswithhypertension andwithmagnetic resonance imaging–confirmed
symptomatic lacunar infarct and confluentwhitematter hyperintensitieswere recruited
betweenFebruary 29, 2012, andOctober 21, 2015, and randomized (36 in the standardgroup
and34 in the intensive group). Analyzabledatawere available in62patients, 33 in the standard
groupand29 in the intensive group, for intent-to-treat analysis. This experiment examines the
3-month follow-upperiod.
INTERVENTIONS Patients were randomized to standard (systolic, 130-140mmHg) or
intensive (systolic, <125mmHg) BP targets, to be achieved throughmedication changes.
MAIN OUTCOMES ANDMEASURES Cerebral perfusionwasmeasured using arterial spin
labeling; the primary end point was change in global perfusion between baseline and 3
months, compared between treatment groups by analysis of variance. Linear regression
compared change in perfusion against change in BP. Magnetic resonance imaging scan
analysis was masked to treatment group.
RESULTS Among 62 analyzable patients, the mean age was 69.3 years, and 60% (n = 37)
were male. Themean (SD) systolic BP decreased by 8 (12) mmHg in the standard group and
by 27 (17) mmHg in the intensive group (P < .001), with mean (SD) achieved pressures of
141 (13) and 126 (10) mmHg, respectively. Change in global perfusion did not differ between
treatment groups: the mean (SD) change was −0.5 (9.4) mL/min/100 g in the standard group
vs 0.7 (8.6) mL/min/100 g in the intensive group (partial η2, 0.004; 95% CI, −3.551 to 5.818;
P = .63). No differences were observed when the analysis examined gray or white matter only
or was confined to those achieving target BP. The number of adverse events did not differ
between treatment groups, with a mean (SD) of 0.21 (0.65) for the standard group and
0.32 (0.75) for the intensive group (P = .44).
CONCLUSIONS AND RELEVANCE Intensive BP lowering did not reduce cerebral perfusion in
severe small vessel disease.
TRIAL REGISTRATION isrctn.org Identifier: ISRCTN37694103
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C erebral small vessel disease (SVD) causes 20% of allischemic strokes1 and is the most common cause ofvascular cognitive impairment.2 It is thought that a
diffuse arteriopathy of the cerebral small vessels results in
hypoperfusion and impaired cerebral autoregulation, with
subsequent ischemia leading to white matter hyperintensi-
ties (WMHs) visible on T2-weighted magnetic resonance
imaging (MRI), as well as lacunar infarction.2
Hypertension is the most important risk factor for SVD.3
Prior studies have reported that more intensive blood pres-
sure (BP) lowering (typically targeting a systolic BP of
approximately 120 mm Hg compared with the standard tar-
get of 140 mm Hg) is associated with a reduction in cardio-
vascular events in primary prevention4 and with decreased
recurrent stroke risk in secondary prevention in unselected
patients with stroke.5 Such approaches may also be benefi-
cial in SVD, but concern has been raised that overzealous BP
lowering could exacerbate hypoperfusion,6 extending
brain injury.
Studies7,8 have shown reduced cerebral blood flow (CBF)
in the white matter (WM) (and normal-appearing WM
[NAWM]) of patients with SVD and have shown that the
degree of hypoperfusion correlates with the severity of
WMHs, consistent with a causal role in the disease patho-
genesis. It has also been demonstrated that the limits of
autoregulation are shifted upward as a consequence of struc-
tural vascular adaptation in individuals with chronic
hypertension.9 This evidence has led to the hypothesis that
a higher systemic BP is required to maintain adequate CBF in
SVD and that excess BP lowering may increase ischemia and
worsen WMHs and cognition.10
However, a 2013 study11 demonstrated that intensive BP
lowering in elderly patients with hypertension without
stroke was associated with increased CBF, hypothetically
due to a reshifting of the cerebral autoregulatory curve. In
addition, a large trial on SVD showed a trend toward reduced
recurrent stroke with intensive BP lowering.12 However,
many patients in that study had isolated lacunar infarction
without WMHs. Whether intensive BP lowering may be asso-
ciated with worse outcome in patients with severe SVD and
confluent WMHs, which is the group in whom severely
reduced CBF and autoregulation have been reported,
remains uncertain. To address this question, we performed a
randomized clinical trial to investigate if standard vs inten-
sive BP lowering in patients with lacunar stroke and conflu-
ent WMHs has different effects on CBF over 3 months.
Methods
PRESERVE Study
The PRESERVE study is an ongoing, 2-year, multicenter, ran-
domized clinical trial that tests standardvs intensiveBP treat-
ment regimens inpatientswithsevereSVDonoutcomesofWM
disease (assessed by diffusion-tensor imaging) and cogni-
tion. This article presents a nested substudy that investigates
CBF change over the first 3 months of the trial. The full pro-
tocol can be found in the Supplement.
Population
Screeningbyanexperiencedneurologist (B.M.,U.K.,orH.S.M.)
ensured that all participants had MRI-confirmed clinical
lacunar stroke, confluentWMHs graded as 2 or higher on the
Fazekas Scale,13 hypertension, andno strokewithin 3months
before study commencement. Detailed inclusion and exclu-
sion criteria have been described previously.14 All patients
gavewritten informedconsent.Thestudywasapprovedby the
Harrow National Research Ethics Service committee and is
registered with the UK Clinical Research Network.
Apowercalculationusingarterial spin labeling (ASL)data15
from elderly controls showed that the planned sample size of
60 was powered at 0.9 to detect a 24% reduction inWM CBF
and a 25% reduction in gray matter (GM) CBF (P = .01). Sev-
enty patients with hypertension were recruited at 2 English
university medical centers (41 at site 1 [St George’s National
Health Service Healthcare Trust] and 29 at site 2 [Newcastle
Hospitals National Health Service Foundation Trust]).
Clinical Assessments
Aneurologist or stroke physician (B.M., U.K., or other nonau-
thors) examined all participants. Cerebrovascular risk factors
were recorded.Ateachparticipantvisit (describedbelow in the
Trial Design, Randomization, andTreatment subsection), ad-
verse events (AEs) and serious AEs (SAEs) were recorded. In
addition to any general problems that had been experienced
(eg, swollenankles), participantswereaskedspecifically about
any falls or postural related dizziness that had occurred since
the last visit. Any events reported were classified by likeli-
hood of having been caused by a study drug (rated as none,
remote, possible, probable, or definite) and classed as falls,
postural related dizziness, or other.
Trial Design, Randomization, and Treatment
The PRESERVE study has a parallel trial design. After recruit-
ment, participants were randomized (stratified via site) to
either the standard (systolic BP target, 130-140 mm Hg) or
intensive (systolic BP target, <125 mm Hg) treatment group
(aiming for a systolic BP difference between treatment
groups of ≥15 mm Hg) in a 1:1 ratio via a centralized, online
system (based at the Mental Health and Neurosciences Clini-
cal Trials Unit, King’s College London) by a research nurse or
physician, who then allocated the participant to the assigned
group. No changes were made to the methods or trial
Key Points
Question Does intensive blood pressure lowering cause
hypoperfusion in severe cerebral small vessel disease?
Findings This randomized clinical trial used arterial spin labeling
to examine the effect of standard (n = 33) vs intensive (n = 29)
blood pressure treatment regimens on cerebral blood flow in
patients with severe small vessel disease over 3 months. Change in
whole-brain cerebral blood flow did not significantly differ
between standard vs intensive groups.
Meaning Intensive blood pressure lowering did not cause
hypoperfusion in severe cerebral small vessel disease.
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outcomes after trial commencement. There were no interim
analyses or stopping guidelines. Treatment allocation
was known to participants and clinical staff (B.M.,
U.K., and other nonauthors), but analysis of data was
performed masked.
Assessments in clinic were performed at baseline, 4
weeks, and 12 weeks. Additional clinic or telephone check-
ups were performed as necessary. Participants took daily
sitting readings with home BP monitors for at least 3 days
before each check-up. During clinic visits, systolic and dia-
stolic BP was measured in a sitting position 3 times after a
10-minute rest period in a quiet room. The recorded BP was
the mean of the second and third measures. At each check-
up, if the participant’s BP was above his or her study target
(and provided that hypotensive symptoms did not prevent
it), an increase in antihypertensive medication was pre-
scribed. Results presented and used in the analysis were
clinic BP readings.
Treatment algorithms for standard and intensive BP
lowering protocols consistent with the British Hypertension
Society/National Institute for Health and Care Excellence
guidance on drug treatment of hypertension were used for
reference.16 Final treatment decisionsweremadeby the local
study principal investigator (U.K. at site 1 andG.A.F. at site 2).
No treatment changes were made for any participant before
he or she had a baseline MRI scan.
End Points
The primary end point was change in whole-brain CBF. Sec-
ondary end points were change in GM,WM, and NAWMCBF.
MRI Protocol
Site 1 used a 3-T Achieva TX imaging system (Philips Medical
Systems),while site 2 initially used a 3-TAchieva (n = 24) and
then a 3-T Achieva TX (n = 5) after an upgrade (all partici-
pants received both scans on the same scanner). At baseline,
the protocol included 3-dimensional (3-D) T1-weighted (T1W)
and2-dimensional fluid-attenuated inversionrecovery (FLAIR)
andpulsedASL sequences. TheT1WandASL sequenceswere
repeated at the 3-month time point. Details of each sequence
are given below.
Sagittal 3-D T1W images included turbo field echo, voxel
size of 1-mm isotropic, field of view (FOV) of 240 × 170mm3,
and repetition time/echo time of 8.27/4.61 milliseconds (site
1) and 9.81/4.60 milliseconds (site 2). Axial FLAIR included
voxel size of 0.48 × 0.48 × 3 mm3, FOV of 230 × 230 mm2,
57 slices, repetition time/echo time of 11 000/120 millisec-
onds, and inversion time of 2800milliseconds.
AxialpulsedASL includedFOVof256 × 256mm2, 10slices,
and inversion time at themost inferior slice of 1500millisec-
onds. Site 1 used echo-planar imaging-based signal targeting
byalternating radiofrequencypulses (EPISTAR),17withavoxel
sizeof3.2 × 3.2 × 6mm3, repetition time/echo timeof4000/27
milliseconds, 40° flip angle, and 120 tag/control pairs. Site 2
used flow-sensitive alternating inversion recovery (FAIR),18
with a voxel size of 4 × 4 × 6 mm3, repetition time/echo
time of 2500/12.59 milliseconds, 90° flip angle, and
100 tag/control pairs.
Additional images were acquired for the ASL sequences.
These included M0 and Geo EPI images for EPISTAR (voxel
size of 3.2 × 3.2 × 6 mm2, FOV of 256 × 256 mm2, 10 slices,
90° flip angle, 1 acquisition, and repetition time/echo time
of 15 000/27 milliseconds for M0 and 500/18 milliseconds
for Geo) and sets of 6 acquisitions at inversion times of 900,
1200, 1800, 2100, and 2400 milliseconds for FAIR (same
acquisition as the main sequence).
To ensure standardization, 4 healthy individuals under-
went the full imaging protocol at each site before study com-
mencement. The ASL datawere preprocessed using standard
techniques to create flow-weighted images, thehistogramsof
which were examined, and consistent results between sites
were found.
Data Processing
ASL Preprocessing
Arterial spin labeling is an MRI technique that quantifies
CBF without exogenous contrast agent. It instead uses the
difference in signal between images where blood has or has
not been magnetically tagged and converts this into CBF (in
milliliters per minute per 100 g) via a model that takes into
account variables such as the efficiency of the magnetic tag.
It shows good agreement with contrast-enhanced MRI in
populations with acute stroke19 and is considered a robust
method of measuring CBF.20
The ASL image series were motion corrected using
automated image registration (http://www.loni.usc.edu
/Software/AIR).21 The difference in signal between average
tag and control imageswas calculated, creating thedifference
image (dm). All tag/control images were averaged to create a
magnitude image (M). The proton density (M0) image was
acquireddifferentlybetweenthe2sequences: forEPISTAR, the
M0 image acquired during scanningwas used,while for FAIR
it was generated by fitting of the inversion recovery curve
(modeled fromtheadditional inversion timeacquisitions).The
dm/M0 images were coregistered to the M image using
Statistical Parametric Mapping 8 (SPM8) (http://www.fil.ion
.ucl.ac.uk/spm/) “coreg.”22
Region-of-Interest Generation
The WMHs were marked on the baseline FLAIR images as
previously described.14 The T1W scans were intensity non-
uniformity corrected (using N4ITK23), tissue segmented
(using “Segment” from Statistical Parametric Mapping 12b),
and registered to their time point respective ASL M image
(using Oxford Centre for Functional MRI of the Brain’s
[FMRIB’s] Linear Image Registration Tool, FMRIB’s Linear
Image Registration Tool,24 and a part of the FMRIB Software
Library25; for site 2, the registration was via the Geo image
to improve registration success). FLAIR scans were regis-
tered to T1W images. Lesion masks and the segmented
tissue probability maps (TPMs) were transformed into
ASL space using these registrations (concatenated
where necessary).
The transformed tissue probability maps were thresh-
olded (at 0.5), binarized, and with the lesion masks used to
create final masks of whole brain, GM, all WM, and NAWM.
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After visual inspection, any voxels that were outside of the
brain (as defined by the M image) were removed from
the masks.
CBF Calculation
Theestimatedsignal inM0imagescausedbycerebrospinal fluid
partial volumewas subtracted fromthe images.Cerebral blood
flow was then calculated26 using MATLAB (version R2015a
8.5.0;MathWorks) (https://uk.mathworks.com/),where blood
longitudinal relaxation time is 1550milliseconds,18bloodtissue
partition coefficient is 0.98 mL/g,27 and inversion time of the
most inferior slice is 1500 milliseconds. Other variables
differed between sequences. For FAIR, slice timing delay is
51milliseconds, inversionefficiency(α) is0.99,andtransitdelay
(Δt) is 458 milliseconds. For EPISTAR, slice timing delay is
41milliseconds, α is 0.9, and Δt is 877.5milliseconds. The CBF
mapswerecalculatedforeachslice(accountingfortimingdelay),
with total CBF for each tissue being an average of CBF across
slices, weighted by the volume per slice.
Statistical Analysis
Analyses were performed using SPSS (version 23; IBM Cor-
poration). Variable distribution was measured by visual
inspection and Kolmogorov-Smirnov test. Key demographic
variables and risk factors were compared between treat-
ment groups by independent t test, Mann-Whitney test, and
χ2 test as appropriate. The number of AEs whose likelihood
of being caused by the study drug had been deemed as
possible/probable/definite was compared between treat-
ment groups by Mann-Whitney test. Baseline CBF values for
whole brain were compared by independent t test between
sites to test for any site-related differences. These analyses
were conducted using all available data, while all subse-
quent analyses considered only participants who returned
usable ASL data sets from both time points.
Systolic and diastolic BP was compared between time
points by paired t tests within each treatment group. Change
insystolic anddiastolicBP (ie, 3-monthminusbaselineBP)was
compared by independent t tests between treatment groups.
End Point Analyses
Analyses were performed on an intent-to-treat basis, were 2
tailed with α = .05, and controlled for site. Change in CBF (ie,
3-month minus baseline CBF) was compared between treat-
ment groups using univariate analysis of variance (ANOVA).
The Bayes factor28 was calculated for the whole-brain CBF
model as an additional means of estimating the strength of
the primary end point finding.
Further secondary analyses repeated the above ANOVA
models but only included intensive group participants who
reached their target vs standard group participants whose
3-month systolicBPexceeded 130mmHg (thus controlling for
participants whose final BP may undermine study assump-
tions). Finally,multivariable linear regressionwas performed
comparingchange inCBF (inall regionsof interest [ROIs])with
change in systolic and diastolic BP.
Levine test of equal variances and inspection for normal
distributionof residualswereconducted toensure thatANOVA
and regressionmodel assumptionsweremet.Anαvalueof .05
was used for all tests.
Results
The PRESERVE trial began recruitment on February 29, 2012.
The last patient included was recruited on October 21, 2015.
Recruitment across all PRESERVE sites closed on October 30,
2015. Patient flow is shown inFigure 1. Sixty-twoparticipants
returned complete, usable data sets (36 at site 1 and 26 at site
2, including 33 in the standard group and 29 in the intensive
group). Across this groupof 62participants, themeanagewas
69.3years, and60%(n = 37)weremale; sexdistributionwithin
treatment groupswas64%(21of 33) in the standardgroupand
55% (16 of 29) in the intensive group. Characteristics of those
who dropped out (n = 6) were descriptively similar to those
who remained in the study. For those who dropped out, the
mean agewas 69.4 years, 4 of 6weremale, themeanbaseline
systolic BP was 152 mm Hg, and the mean baseline Montreal
CognitiveAssessment (MoCA) scorewas24.50. For thosewho
stayed in the study, the mean age was 69.5 years, 61% (39 of
64) weremale, themean baseline systolic BPwas 151mmHg,
and the mean baseline MoCA was 24.72.
Demographicswithin treatmentgroupsare listed inTable1.
No variable was significantly different between groups.
Baselinewhole-brainCBFdidnotdifferbetweenthe2sites.
Themean (SD) at site 1 was 30.7 (11.3) mL/min/100 g, and the
mean (SD) at site 2 was 33.7 (10.2) mL/min/100 g (P = .25).
BPMeasurements in the 2 Treatment Groups
Themean systolic/diastolic BP changed from 150/83mmHg at
baseline to141/79mmHgat3months in thestandardgroupand
Figure 1. CONSORTDiagram
36 Randomized to (and received)
standard treatment
34 Randomized to (and received)
intensive treatment
33 Analyzed 29 Analyzed
0 Further exclusions 2 Further exclusions
2 Excluded due to noise
artifacts/data corruption on
FLAIR images preventing
lesion marking
3 Lost to follow-up
1 Withdrew from study as did
not wish to continue
1 Did not attend due to MRI
scheduling problems
1 Withdrew from ASL substudy
3 Lost to follow-up
1 Withdrawn from study due to
not meeting criteria on review
(Fazekas Scale score <2)
1 Did not attend due to MRI
scheduling problems
1 Withdrew from ASL substudy
70 Randomized
Shown is an overview of the participant flow, sample sizes, and dropout
characterization for this analysis. ASL indicates arterial spin labeling;
CONSORT, Consolidated Standards of Reporting Trials; FLAIR, fluid-attenuated
inversion recovery; andMRI, magnetic resonance imaging.
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from154/88mmHgatbaseline to 126/75mmHgat 3months in
the intensive group, achieving a between-group separation of
15mmHg (systolic). Therefore, themean (SD) systolic/diastolic
BP change was 8 (12)/4 (9) mm Hg in the standard group and
27 (17)/13 (13)mmHg in the intensive group. Change in systolic
and diastolic BPwas significantly different between treatment
groups(P < .001forsystolicandP = .002fordiastolic)andwithin
treatment groups (standard group P = .001 for systolic and
P = .02 for diastolic; intensive group P < .001 for systolic and
P < .001fordiastolic).At3months, 13of33(39%)standardgroup
participants and 18 of 29 (62%) intensive group participants
had reached their BP targets.
Change in CBF Between Treatment Groups
Cerebral blood flow values across the entire sample were
31.6 mL/min/100 g for whole brain, 45.1 mL/min/100 g for
GM, 22.0 mL/min/100 g for all WM, and 22.8 mL/min/100 g
for NAWM. Baseline CBF values did not differ between
treatment groups in any ROI. Individual participant change
in CBF by treatment group is shown in Figure 2.
Theprimaryendpoint, change inwhole-brainCBF,didnot
differ between the 2 treatment groups: the mean (SD) change
was −0.5 (9.4) mL/min/100 g in the standard group vs 0.7
(8.6)mL/min/100gintheintensivegroup(partialη2,0.004;95%
CI[basedonestimatedmarginalmeans],−3.551to5.818;P = .63).
The Bayes factor was 0.217 (ie, these findings were 4.61 times
more likely tooccurunder thenullhypothesis, givingmoderate
support for thenull according toconventional interpretation.29
Therewerenodifferences inCBFchangebetweentreatment
groups for GM, allWM, orNAWM.Table 2 lists the full results.
Secondary Analyses
Further secondary analyses showed no association between
change in systolic/diastolic BP and change in CBF: the
systolic/diastolic P values for ROIs were .73/.88 for whole
brain, .67/.87 for GM, .60/.71 for all WM, and .65/.75 for
NAWM. There were no differences in CBF change when
groups were restricted to standard group participants whose
final systolic BP exceeded 130 mm Hg (n = 29) and intensive
group participants who reached their target BP (n = 18)
(P = .89 for whole brain, P = .93 for GM, P = .95 for all WM,
and P = .97 for NAWM). Table 3 lists the full results.
Adverse Events
Mann-Whitney test showed no di f ference in the
number of study drug–related AEs between the 2 groups,
with a mean (SD) of 0.21 (0.65) (median, 0) for the
standard group and a mean (SD) of 0.32 (0.75) (median, 0)
for the intensive group (P = .44). Adverse events were
Table 1. Overview of Demographic and Risk Factor InformationWithin Each Treatment Groupa
Variable
Standard
(n = 36)
Intensive
(n = 34) P Valueb
Age, mean (SD), y 68.64 (7.92) 70.31 (9.76) .44
Sex (male:female), No. (%) 24:12 (67:33) 19:15 (56:44) .35
Race/ethnicity (white:nonwhite), No. (%) 29:7 (81:19) 29:5 (85:15) .60
Days from stroke to scan, mean (SD)c 189.11 (129.64) 202.53 (198.02) .85
Days between baseline and 3-mo scan (if available), mean (SD) 94.45 (14.86) 97.71 (27.37) .55
No. of baseline BP medications, mean (SD) 1.53 (1.13) 1.56 (0.96) .82
Previous stroke (no:yes), No. (%) 30:6 (83:17) 29:5 (85:15) .82
BP, mean (SD)
Systolic 150 (10) 153 (12) .21
Diastolic 84 (10) 87 (13) .23
MoCA (total), mean (SD) 24.39 (4.02) 25.03 (3.68) .49
History of depression (no:yes), No. (%) 28:8 (78:22) 29:5 (85:15) .42
History of cognitive decline (no:yes), No. (%) 23:13 (64:36) 22:12 (65:35) .94
Diabetes (no:yes), No. (%) 29:7 (81:19) 25:9 (74:26) .48
Smoker (no:yes), No. (%)
Current 28:8 (78:22) 31:3 (91:9) .12
Former 24:11 (69:31) 22:11 (67:33) .99
Angina (no:yes), No. (%) 32:4 (89:11) 32:2 (94:6) .44
Myocardial infarction (no:yes), No. (%) 34:2 (94:6) 32:2 (94:6) .95
Peripheral vascular disease (no:yes), No. (%)d 34:1 (97:3) 33:1 (97:3) .98
Drug-treated hypercholesterolemia (no:yes), No. (%) 4:32 (11:89) 10:24 (29:71) .06
Abbreviations: BP, blood pressure;
MoCA, Montreal Cognitive
Assessment.
a Data are presented as means (SDs)
for continuous data and as
unadjusted ratios (percentages) for
frequency data. Some totals do not
sum to heading totals because of
missing data.
bP values (all nonsignificant)
compare the treatment groups by
groupwise (t tests or Mann-Whitney
tests) and χ2 analyses as
appropriate.
c Data are missing for 5 participants
(1 standard and 4 intensive).
dData are missing for 1 participant
(standard).
Figure 2. Change inWhole-Brain Cerebral Blood Flow (CBF)
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The spaghetti plot shows the change for each participant by treatment group.
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reported 29 times, in 17 participants (9 intensive and 8 stan-
dard), and were deemed to be related to the study drug in 17
cases, among 10 participants (6 intensive and 4 standard).
There was no difference between groups in the number of
falls (1 each) or postural related dizziness (2 each). No SAEs
were recorded.
Table 3. Descriptive and Statistical Values for All Other Secondary End Point Analysesa
Variable Whole-Brain ROI Gray Matter ROI All White Matter ROI
Normal-Appearing
White Matter ROI
Restricted Standard CBF (n = 29)
Baseline/3-mo CBF 31.0 (10.0)/31.0 (11.8) 43.6 (13.6)/44.9 (17.6) 21.6 (6.9)/21.6 (7.9) 22.4 (7.0)/22.4 (8.3)
CBF change 0.0 (9.3) [P = .99] 1.3 (13.7) [P = .61] 0.0 (6.6) [P = .99] 0.0 (6.8) [P = .98]
Restricted Intensive CBF (n = 18)
Baseline/3-mo CBF 31.1 (11.4)/31.2 (15.2) 43.2 (17.0)/43.8 (22.4) 22.2 (7.5)/22.0 (8.8) 23.0 (7.6)/22.9 (9.3)
CBF change 0.1 (10.6) [P = .96] 0.5 (14.7) [P = .88] −0.2 (6.5) [P = .89] −0.1 (6.9) [P = .95]
ANOVA Findings (Standard vs Intensive Change in CBF Restricted by Achieved BP Target
Treatment group findings F1,43 = 0.021,
partial η2<0.001, P = .89
F1,43 = 0.008,
partial η2<0.001, P = .93
F1,43 = 0.004,
partial η2<0.001, P = .95
F1,43 = 0.001,
partial η2<0.001, P = .97
Estimated model means standard
vs intensive difference
Group difference, 0.433;
95% CI, −5.563 to 6.430
Group difference, −0.389;
95% CI, −9.021 to 8.243
Group difference, −0.122;
95% CI, −4.206 to 3.963
Group difference, −0.078;
95% CI, −4.320 to 4.165
Site findings F1,43 = 2.264, P = .14 F1,43 = 1.599, P = .21 F1,43 = 0.925, P = .34 F1,43 = 0.765 P = .39
Model-adjusted R2 −0.014 −0.029 −0.044 −0.046
Change in CBF vs Change in BP Regression Models (All Participants Systolic BP)
Change in BP β −0.046; 95% CI,
−0.111 to 0.158 (P = .73)
−0.056, 95% CI,
−0.155 to 0.241 (P = .67)
−0.069, 95% CI,
−0.070 to 0.120 (P = .60)
−0.060, 95% CI,
−0.076 to 0.122 (P = .65)
Site β −0.137 (P = .29) −0.106 (P = .42) −0.062 (P = .63) −0.053 (P = .69)
Model-adjusted R2 −0.011 −0.018 −0.024 −0.027
Change in CBF vs Change in BP Regression Models (All Participants Diastolic BP)
Change in BP β −0.019; 95% CI,
−0.182 to 0.211 (P = .88)
0.022; 95% CI,
−0.315 to 0.267 (P = .87)
−0.050; 95% CI,
−0.133 to 0.166 (P = .71)
−0.041; 95% CI,
−0.122 to 0.168 (P = .75)
Site β −0.138 (P = .29) −0.115 (P = .38) −0.061 (P = .64) −0.052 (P = .69)
Model-adjusted R2 −0.013 −0.021 −0.027 −0.029
Abbreviations: ANOVA, analysis of variance; BP, blood pressure; CBF, cerebral
blood flow; ROI, region of interest.
a Cerebral blood flow values (milliliters per minute per 100 g) presented as
means (SDs) are given at both time points in treatment groups restricted by
achieved BP (where 3-month systolic values were <125mmHg for intensive
group participants and >130mmHg for standard group participants), with
paired t test results comparing these values given below these. Univariate
ANOVA findings are also shown comparing change in CBF between these
groups (controlling for site). The 95% CIs are given based on estimated
marginal means for the difference in change in CBF between groups. Results
from linear regression comparing change in BP vs change in CBF (across all
participants) are shown.
Table 2. CBF Values at Baseline and 3Months in the 2 Treatment Groups,With Primary and Initial Secondary End Point ANOVAResultsa
Variable Whole-Brain ROI Gray Matter ROI All White Matter ROI
Normal-Appearing
White Matter ROI
Standard CBF (n = 33)
Baseline/3-mo CBF 32.1 (10.1)/31.7 (12.3) 45.7 (14.3)/46.0 (18.3) 22.3 (7.0)/21.9 (8.3) 23.1 (7.0)/22.7 (8.6)
CBF change −0.5 (9.4) [P = .78] 0.3 (14.2) [P = .91] −0.5 (7.0) [P = .71] −0.5 (7.2) [P = .72]
Intensive CBF (n = 29)
Baseline/3-mo CBF 31.1 (10.4)/31.8 (13.2) 44.4 (15.4)/45.7 (18.7) 21.5 (6.6)/21.9 (8.0) 22.5 (7.0)/23.0 (8.6)
CBF change 0.7 (8.6) [P = .65] 1.3 (12.2) [P = .58] 0.4 (5.6) [P = .69] 0.5 (5.8) [P = .64]
ANOVA Findings (Standard vs Intensive Change in CBF)
Treatment group findings F1,58 = 0.235,
partial η2 = 0.004, P = .63
F1,58 = 0.049,
partial η2 = 0.001, P = .83
F1,58 = 0.231,
partial η2 = 0.004, P = .63
F1,58 = 0.256,
partial η2 = 0.004, P = .62
Estimated model means
standard vs intensive
difference
Group difference, 1.133;
95% CI, −3.551 to 5.818
Group difference, 0.765;
95% CI, −6.170 to 7.700
Group difference, −0.800;
95% CI, −2.535 to 4.136
Group difference, 0.872;
95% CI, −2.579 to 4.323
Site findings F1,58 = 1.319, P = .26 F1,58 = 0.824, P = .37 F1,58 = 0.334, P = .57 F1,58 = 0.255, P = .62
Model adjustment R2 0.019 0.028 0.038 0.036
Abbreviations: ANOVA, analysis of variance; BP, blood pressure; CBF, cerebral
blood flow; ROI, region of interest.
a Paired t test results that compare change in CBF (milliliters per minute
per 100 g) presented as means (SDs) within treatment groups are given below
the descriptive values. Univariate ANOVA findings are also shown comparing
change in CBF between each treatment group (controlling for site). The 95%
CIs are given based on estimatedmarginal means for the difference in change
in CBF between groups. The gray matter CBFmodel failed the Levine test of
equal variances; this analysis was repeated using the Kruskal-Wallis test
(without controlling for site) and remained nonsignificant (P = .94).
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Discussion
In this randomized clinical trial, we investigated the
effect of standard vs intensive BP lowering on CBF
in patients with severe symptomatic SVD, as manifested
by both lacunar stroke and confluent WMHs. Our
results showed no difference in change in CBF (of any
studied ROI) over the 3-month follow-up period between
the 2 treatment groups. Furthermore, we found no excess of
AEs in the intensive group, including potential ly
hypotension-related events. This provides support that
intensive BP reduction regimens do not cause hypoperfu-
sion in patients with severe symptomatic SVD.
Intensive BP lowering has been shown to reduce
cardiovascular end points in patients without previous car-
diovascular disease.4 However, there is concern that it may
be hazardous in patients with extensive SVD, in whom
reduced CBF and impaired cerebral autoregulation have
been previously demonstrated.10 Therefore, our results are
reassuring that intensive treatment can be used in this
patient cohort.
These findings complement the Secondary Prevention
of Small Subcortical Strokes 3 trial,12 which did not
measure CBF but applied a similar BP regimen to patients
with MRI-confirmed lacunar stroke (but not necessarily
confluent WMHs). The intensive treatment was tolerated
compared with the standard treatment with regard to out-
comes such as SAEs and also showed a trend toward a
reduced stroke rate. However, our findings do not support
previous work in patients with hypertension without stroke
or SVD,11 which found that intensive treatment raised CBF
via resetting of the cerebral autoregulatory curve. This may
be due to patients with SVD having more severe cerebrovas-
cular disease than the elderly participants with hyperten-
sion included in that study, meaning that a potential
increase either may not be possible because of the extent of
their preexisting damage or may take longer to achieve.
The PRESERVE study will investigate this last point when
the 2-year study is completed.
Limitations
Our studyhas limitations.TheASLsequencesdifferedslightly;
however, baselineCBFvalueswerenot significantly different
betweensites.Becauserandomizationwasstratifiedacrosssites,
thisshouldnothaveinfluencedanyanalyses.Theyearthestudy
wasplanned(2010-2011)alsorestrictedASLtechniques;assuch
(and tomaintaindata consistency throughout the studydura-
tion), recent advances suchasQUIPSS (quantitative imagingof
perfusion using a single subtraction) were not used. The lack
of a FLAIR scan at the 3-month time point means that new
WMHswould be classified asNAWMat follow-up (butNAWM
findingsdidnotdiffer fromotherROIs, sothis isunlikely tohave
affected any interpretation). Althoughweachievedour target
treatmentgroupBPdifferenceof 15mmHg(systolic), only62%
(18 of 29) of intensive group participants reached their target.
Thisdiminishespower for theprimaryandsecondaryANOVAs
(bydatanoiseandlownumbers, respectively).While theregres-
sionanalysis (whichwouldbeunaffectedby this) also supports
our conclusionof no connectionbetweenBPandCBFchange,
these considerations, aswell as theBayes factor showingmod-
erate support for thenull hypothesis,mean that interpretation
shouldbeapproachedwithadegreeofcaution.Finally,because
patientswho had a strokewithin 3monthswere ineligible for
the study, our findings are not applicable to acute poststroke
treatment.
Conclusions
While 38% (11 of 29) of intensive group patients failed to reach
theirtargetBP,ouroverall findingsareconsistentwiththerebeing
no association between BP lowering and change in CBF (or in-
creasedclinicalAEs)overa3-monthperiodcomparedwithstan-
dardBP lowering.This suggests that intensiveBP loweringdoes
not cause cerebral hypoperfusion in patientswith severe SVD.
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